Mochi Health vs Hims & Hers

Mochi Health vs Hims & Hers at every dose

A single headline figure assumes a maintenance dose neither you nor your prescriber has chosen yet. This is the same comparison at all six strengths.

What differs beyond price

Price is the easiest thing to compare and rarely the thing that decides satisfaction. These are the attributes each programme publishes.

Which one, for whom

If you want the lowest total cost: Mochi Health at about $2,136 for a first year.

If you want budget certainty: neither has an advantage — both use the same pricing model.

If you want to verify the supply chain: neither names a dispensing pharmacy in a way we could verify — ask both directly.

If you may need to stop early: compare the cancellation rows above before prepaying. Compounded medication is generally not refundable once it has shipped, so a multi-month term is the wrong structure during titration, when intolerance is the most likely reason to stop.

Switching between them

Usually possible after a clinical review, and the two real risks are a supply gap while a new intake is processed and a new prescriber restarting titration rather than continuing your dose. Confirm dose continuity in writing before cancelling anything, because a month back at 0.25 mg is a month of lost progress no price difference recovers.

If you are already on one of them

Moving from Hims & Hers to Mochi Health is worth $252 over a year. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that a new prescriber restarts titration rather than continuing your dose. Ask about dose continuation in writing before cancelling anything, because a month back at 0.20.5 mg is a month of lost progress no price difference recovers.

Fee structure, side by side

Mochi Health charges a mandatory membership of $79 a month on top of medication. Hims & Hers charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

Mochi Health: video, labs optional, dietitian access. Hims & Hers: async, labs optional, included.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

Mochi Health: owned facility. Hims & Hers: brand only since Mar 2026.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

Which is cheaper depends on where you land

A single annual comparison assumes one maintenance dose. This runs both programmes at every plausible outcome, over one year and three.

Read the final column before the first. A gap that looks modest over twelve months compounds into the three-year figure, and the withdrawal evidence for this drug class means three years is the more honest planning horizon.

What each one is actually charging for

Mochi Health: $99 medication plus $79 platform fee, $948 a year. Hims & Hers: $199 medication, no recurring fee.

Comparing the medication figures alone would make Mochi Health look $79 a month cheaper than it is. That is the single most common distortion in published comparisons of these two.

What $252 a year actually buys

The gap over a first year is $252, about 11% of the larger figure and roughly 1.4 months of therapy at Mochi Health's maintenance rate. Over three years at a stable dose the same difference compounds to about $756.

Whether that is decisive depends on what Hims & Hers provides that Mochi Health does not. On the published record Hims & Hers offers async against video, and its pharmacy disclosure reads brand only since Mar 2026 against owned facility.

If the difference is nothing you will use, the gap is simply a gap. If it includes clinician access during titration, when dose questions arrive weekly, it may be the better purchase — but that is a judgement about your first three months rather than about the annual total.

How the pricing models interact

Both hold one price across the full 0.25 to 2.4 mg ladder, so this comparison does not move with your dose. Whatever your prescriber decides, Mochi Health stays $21 a month cheaper at every strength.

That makes the decision unusually clean: price is settled, so decide on disclosure, care model and terms. It is also worth noticing because semaglutide titration is slower than most patients expect — four weeks minimum at each step, frequently longer for tolerability — so a dose-scaled programme would have had months to reprice you.

The fee structures are not the same purchase

Mochi Health bills $79 a month as a platform fee on top of medication; Hims & Hers charges none.

Over three years that difference alone is $2,844, and it is the component most likely to be missing from any comparison you read elsewhere. Published tables tend to compare medication prices rather than totals, which flatters whichever programme charges the larger fee.

A membership earns its cost when you use it. During titration, unlimited clinician messaging is genuinely valuable — semaglutide's gastrointestinal effects cluster in the first weeks after each step up. At stable maintenance it is close to idle. Ask what happens to your prescription if the membership lapses mid-supply.

Committing to a term changes the answer, and the risk

Mochi Health publishes no prepaid rate; Hims & Hers publishes none.

Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. Entering a term during titration commits cash against the most likely reason to stop, which is not tolerating the drug.

The sequencing that protects you: monthly billing until you have held a maintenance dose for a full cycle, then a term once the main reason to stop has passed. Two questions first, both answerable in writing — does the rate hold for the whole term, and what happens if a clinician stops your prescription mid-term.

Both figures carry the same evidence grade

Both are recorded as third party reported, so the comparison is at least like for like. That is not the same as both being right: a shared grade means we applied one standard, not that the numbers were confirmed twice.

Each programme page links the source we captured with a Wayback lookup beside it. Two minutes of checking beats any assurance we could offer.

Moving from Hims & Hers to Mochi Health, and what it costs

The arithmetic is $252 over a year. Two things eat it: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Semaglutide titration runs at least sixteen weeks from 0.25 mg to 2.4 mg when every step goes smoothly, so a restart can cost a third of a year. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

Take three things with you: your current dose and the date you reached it, the concentration printed on your current vial, and any record of adverse effects with dates. Concentrations are not standardised between compounders, and carrying instructions from an old vial to a new one is a real hazard rather than a theoretical one.

What neither table can tell you

Whether shipments arrive on time, how fast a clinician replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does.

We hold no measurements of any of them we would defend, so they appear nowhere in our tables rather than being estimated into a score. The usable proxy is what each programme publishes before it has your money — and Mochi Health and Hims & Hers can be judged on that today.

Re-run this at your actual maintenance dose annually. Programmes do not notify existing patients when a competitor drops below them, and semaglutide pricing moved repeatedly through 2025 and 2026.

If your titration runs slower than the schedule

The approved ladder moves every four weeks, and a large share of patients hold at a step longer because of nausea or reflux. Add two extra months before maintenance and Mochi Health costs $356 more that year against $398 at Hims & Hers.

On flat pricing an extra month costs the maintenance rate regardless of the dose delivered, which is the one scenario where flat pricing works against you. On dose-scaled pricing it costs less but reproduces a step you had already paid for.

Neither is a reason to choose differently alone. It is a reason to run both one step slower than you expect and take the higher figure into the decision.

The three-year exposure

At maintenance the annual difference is $252 and over three years $756. Three years is the honest horizon rather than a rhetorical one: the withdrawal evidence for this drug class shows substantial regain after stopping.

The realistic question is not what a year costs but whether you can sustain the programme indefinitely. A programme abandoned for cost in month fourteen has cost more than the dearer one you would have kept, because the interruption undoes the result the spending bought.

The decision from Mochi Health's side

You would choose Mochi Health if its structure matches your expected course: flat pricing suits an uncertain or escalating titration, the $79 platform fee is worth paying if you will use clinician access, and its entry price of $178 sets your first month.

You would not choose it if the opposite is true of your course, or if the disclosure rows leave a question you cannot get answered in writing.

The decision from Hims & Hers's side

You would choose Hims & Hers if its flat rate protects you against a dose increase you cannot predict, and if a single all-in figure is what you want. Its first month costs $199 and its maintenance rate is $199.

You would not choose it if the $252 first-year gap is decisive for your budget and nothing in its disclosure justifies the difference.

Putting mochi health and hims & hers in proportion

It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.

The frame: 20 programmes publish a capturable price, spanning $145 to $324 a month all-in at a 2.4 mg maintenance dose. 4 charge a mandatory recurring fee. 6 name the dispensing pharmacy before purchase.

What good looks like

A figure at a named dose, the pharmacy named, cancellation terms published before payment, and a plain statement that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority does all four.

The cheapest verified route sits at $145 a month, which establishes that disclosure and low price are not in tension.

What to ask before you pay

Five questions, all answerable in a short email, all before a medical history changes hands: the total at a maintenance dose including every fee; which pharmacy fills it; whether the prescriber is licensed in your state; the notice period to cancel and what is refundable; and which form of the active ingredient the pharmacy compounds from.

None requires clinical training to evaluate. The speed and specificity of the reply tells you how the operation is run, and it arrives before your money does.

Reading this alongside the rest of the site

Pricing pages isolate one component. Provider reviews carry the whole record for one programme. Comparisons run two side by side at every dose. The rankings sort the same dataset on different questions. None is the whole picture and none is meant to be.

If you read one other page, make it how to verify a pharmacy. Price is the easiest thing to compare and rarely the thing that goes wrong.

What we would need to change our mind

A programme publishing a figure at a dose tier currently blank. A named dispensing pharmacy with a checkable licence. A pricing model changing in either direction. A regulatory action. Or a correction from a reader with a source we can open.

All five are logged with the date they landed, on the change log and in the dataset. Prices here were captured 2026-08-05.

What this site will not do

Publish an estimated price for a programme that does not publish one. Rank a programme higher because it pays. Present a compounded preparation as equivalent to an approved product. Or carry a figure without the date it was captured.

Those four rules cost us pages, rankings and revenue, and they are the only reason a reader has to prefer this to a round-up assembled in an afternoon. A price without its date is not a fact, and a comparison built from undated prices is not a comparison.

Who this site is not for

Anyone with coverage under a documented indication, who should use it rather than read a cash comparison. Anyone looking for a source without a prescription, which this site will not help with. And anyone wanting a single confident recommendation, because the honest answer depends on your dose, your coverage and your tolerance for commitment.

If you want the short version anyway: price the dose you will hold, add every fee, verify the pharmacy, and avoid long prepaid terms until you have tolerated a maintenance dose for a cycle.

Where the money actually separates

A single annual figure hides when the gap opens. Tracked month by month through a first year you can see whether the difference is front-loaded during titration or accumulates quietly at maintenance.

Across the year the gap reaches $252, roughly 11% of the larger total and about 1.4 months of therapy at Mochi Health's maintenance rate. Over three years at a stable dose the same difference compounds to roughly $756.

Does the answer change with your dose?

Mochi Health is cheaper at every strength, so this comparison does not turn on where you settle. The decision moves to what else differs: disclosure, care model, commitment terms and behaviour when a shipment fails.

Commitment and what each puts at risk

Mochi Health publishes no prepaid term. Hims & Hers publishes no prepaid term.

Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. During titration that is the wrong structure: it commits against the most likely reason to stop. After a stable cycle at maintenance it is reasonable.

Care model and what you can verify

Mochi Health: video, labs optional, pharmacy owned facility, cancellation membership recurring.

Hims & Hers: async, labs optional, pharmacy brand only since Mar 2026, cancellation membership recurring.

Where one names a pharmacy and the other does not, that difference outranks a modest price gap. It is the only disclosure that lets you check a public register before injecting something weekly, and it costs a programme nothing to publish.

If you are already on one of them

Moving from Hims & Hers to Mochi Health is worth $252 over a year, about 1.4 months of therapy at the cheaper rate. Set that against two real switching costs: a supply gap while an intake is reviewed, and the possibility that a new prescriber restarts titration.

Ask about dose continuation in writing before cancelling anything. A month back at 0.20.5 mg is a month of lost progress that no price difference recovers, and it is the most common regret reported by people who switched for a small saving.

What neither table can tell you

Shipping reliability, how fast a clinician actually replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does, and we hold no measurements of them we would defend, so they are absent rather than estimated.

The one usable proxy is what each programme publishes before it has your money. A programme that states its price at every dose, names its pharmacy and puts cancellation terms in writing has already told you something about how it behaves when there is a problem.

Running this comparison again later

Both figures carry a capture date and both will change. Programmes do not notify existing patients when a competitor drops below them, and several tracked programmes moved pricing more than once in the past year.

Re-run this at your actual maintenance dose annually, and treat any figure older than a month as needing a re-check before you act on it.

Where both of these sit in the wider market

Mochi Health at $2,136 and Hims & Hers at $2,388 for a first year sit against a market running from $1,740 to $3,625. Both are at the cheaper end of what we track.

If neither is close to the cheapest tracked route, the useful question is not which of these two wins but why you are choosing between these two at all. The comparison matrix will show what else is available at your dose in about ten seconds.

If you are already on one of them

Moving from Hims & Hers to Mochi Health is worth $252 over a year. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that a new prescriber restarts titration rather than continuing your dose. Ask about dose continuation in writing before cancelling anything, because a month back at 0.20.5 mg is a month of lost progress no price difference recovers.

Fee structure, side by side

Mochi Health charges a mandatory membership of $79 a month on top of medication. Hims & Hers charges no recurring fee.

This is where most published comparisons break. A table quoting medication alone understates a membership programme by the full fee, every month, for as long as you stay. Every figure here folds it in, which is why our number can be higher than the one on a programme's own homepage.

Care model and what it buys

Mochi Health: video, labs optional, dietitian access. Hims & Hers: async, labs optional, included.

Video visits, included laboratory work and real clinician access cost money to provide, and programmes providing them are rarely cheapest. That is what you are paying for. The failure is paying a premium for an asynchronous questionnaire a cheaper programme provides identically.

Verification, which outranks both

Mochi Health: owned facility. Hims & Hers: brand only since Mar 2026.

A programme that will not name the pharmacy compounding your medicine is asking you to inject an unidentified preparation weekly. State boards publish licensee registers and FDA publishes outsourcing-facility registrations and warning letters, all free and searchable — but only if you have a name. That question outranks a price difference of almost any size.

Which is cheaper depends on where you land

A single annual comparison assumes one maintenance dose. This runs both programmes at every plausible outcome, over one year and three.

Read the final column before the first. A gap that looks modest over twelve months compounds into the three-year figure, and the withdrawal evidence for this drug class means three years is the more honest planning horizon.

What each one is actually charging for

Mochi Health: $99 medication plus $79 platform fee, $948 a year. Hims & Hers: $199 medication, no recurring fee.

Comparing the medication figures alone would make Mochi Health look $79 a month cheaper than it is. That is the single most common distortion in published comparisons of these two.

What $252 a year actually buys

The gap over a first year is $252, about 11% of the larger figure and roughly 1.4 months of therapy at Mochi Health's maintenance rate. Over three years at a stable dose the same difference compounds to about $756.

Whether that is decisive depends on what Hims & Hers provides that Mochi Health does not. On the published record Hims & Hers offers async against video, and its pharmacy disclosure reads brand only since Mar 2026 against owned facility.

If the difference is nothing you will use, the gap is simply a gap. If it includes clinician access during titration, when dose questions arrive weekly, it may be the better purchase — but that is a judgement about your first three months rather than about the annual total.

How the pricing models interact

Both hold one price across the full 0.25 to 2.4 mg ladder, so this comparison does not move with your dose. Whatever your prescriber decides, Mochi Health stays $21 a month cheaper at every strength.

That makes the decision unusually clean: price is settled, so decide on disclosure, care model and terms. It is also worth noticing because semaglutide titration is slower than most patients expect — four weeks minimum at each step, frequently longer for tolerability — so a dose-scaled programme would have had months to reprice you.

The fee structures are not the same purchase

Mochi Health bills $79 a month as a platform fee on top of medication; Hims & Hers charges none.

Over three years that difference alone is $2,844, and it is the component most likely to be missing from any comparison you read elsewhere. Published tables tend to compare medication prices rather than totals, which flatters whichever programme charges the larger fee.

A membership earns its cost when you use it. During titration, unlimited clinician messaging is genuinely valuable — semaglutide's gastrointestinal effects cluster in the first weeks after each step up. At stable maintenance it is close to idle. Ask what happens to your prescription if the membership lapses mid-supply.

Committing to a term changes the answer, and the risk

Mochi Health publishes no prepaid rate; Hims & Hers publishes none.

Prepaying lowers the rate and makes the money effectively unrecoverable, because compounded medication is generally not refundable once shipped. Entering a term during titration commits cash against the most likely reason to stop, which is not tolerating the drug.

The sequencing that protects you: monthly billing until you have held a maintenance dose for a full cycle, then a term once the main reason to stop has passed. Two questions first, both answerable in writing — does the rate hold for the whole term, and what happens if a clinician stops your prescription mid-term.

Both figures carry the same evidence grade

Both are recorded as third party reported, so the comparison is at least like for like. That is not the same as both being right: a shared grade means we applied one standard, not that the numbers were confirmed twice.

Each programme page links the source we captured with a Wayback lookup beside it. Two minutes of checking beats any assurance we could offer.

Moving from Hims & Hers to Mochi Health, and what it costs

The arithmetic is $252 over a year. Two things eat it: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Semaglutide titration runs at least sixteen weeks from 0.25 mg to 2.4 mg when every step goes smoothly, so a restart can cost a third of a year. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

Take three things with you: your current dose and the date you reached it, the concentration printed on your current vial, and any record of adverse effects with dates. Concentrations are not standardised between compounders, and carrying instructions from an old vial to a new one is a real hazard rather than a theoretical one.

What neither table can tell you

Whether shipments arrive on time, how fast a clinician replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. Those decide satisfaction more than price does.

We hold no measurements of any of them we would defend, so they appear nowhere in our tables rather than being estimated into a score. The usable proxy is what each programme publishes before it has your money — and Mochi Health and Hims & Hers can be judged on that today.

Re-run this at your actual maintenance dose annually. Programmes do not notify existing patients when a competitor drops below them, and semaglutide pricing moved repeatedly through 2025 and 2026.

If your titration runs slower than the schedule

The approved ladder moves every four weeks, and a large share of patients hold at a step longer because of nausea or reflux. Add two extra months before maintenance and Mochi Health costs $356 more that year against $398 at Hims & Hers.

On flat pricing an extra month costs the maintenance rate regardless of the dose delivered, which is the one scenario where flat pricing works against you. On dose-scaled pricing it costs less but reproduces a step you had already paid for.

Neither is a reason to choose differently alone. It is a reason to run both one step slower than you expect and take the higher figure into the decision.

The three-year exposure

At maintenance the annual difference is $252 and over three years $756. Three years is the honest horizon rather than a rhetorical one: the withdrawal evidence for this drug class shows substantial regain after stopping.

The realistic question is not what a year costs but whether you can sustain the programme indefinitely. A programme abandoned for cost in month fourteen has cost more than the dearer one you would have kept, because the interruption undoes the result the spending bought.

The decision from Mochi Health's side

You would choose Mochi Health if its structure matches your expected course: flat pricing suits an uncertain or escalating titration, the $79 platform fee is worth paying if you will use clinician access, and its entry price of $178 sets your first month.

You would not choose it if the opposite is true of your course, or if the disclosure rows leave a question you cannot get answered in writing.

The decision from Hims & Hers's side

You would choose Hims & Hers if its flat rate protects you against a dose increase you cannot predict, and if a single all-in figure is what you want. Its first month costs $199 and its maintenance rate is $199.

You would not choose it if the $252 first-year gap is decisive for your budget and nothing in its disclosure justifies the difference.

Putting mochi health and hims & hers in proportion

It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.

The frame: 20 programmes publish a capturable price, spanning $145 to $324 a month all-in at a 2.4 mg maintenance dose. 4 charge a mandatory recurring fee. 6 name the dispensing pharmacy before purchase.

What good looks like

A figure at a named dose, the pharmacy named, cancellation terms published before payment, and a plain statement that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority does all four.

The cheapest verified route sits at $145 a month, which establishes that disclosure and low price are not in tension.

What to ask before you pay

Five questions, all answerable in a short email, all before a medical history changes hands: the total at a maintenance dose including every fee; which pharmacy fills it; whether the prescriber is licensed in your state; the notice period to cancel and what is refundable; and which form of the active ingredient the pharmacy compounds from.

None requires clinical training to evaluate. The speed and specificity of the reply tells you how the operation is run, and it arrives before your money does.